1 Department of Pediatrics, Division of Pediatric Pulmonology and Sleep Medicine, and.
2 Department of Electrical Engineering, University of California-Los Angeles, Los Angeles, California.
Ann Am Thorac Soc. 2018 Jan;15(1):49-58. doi: 10.1513/AnnalsATS.201702-101OC.
Pediatric asthma has variable underlying inflammation and symptom control. Approaches to addressing this heterogeneity, such as clustering methods to find phenotypes and predict outcomes, have been investigated. However, clustering based on the relationship between treatment and clinical outcome has not been performed, and machine learning approaches for long-term outcome prediction in pediatric asthma have not been studied in depth.
Our objectives were to use our novel machine learning algorithm, predictor pursuit (PP), to discover pediatric asthma phenotypes on the basis of asthma control in response to controller medications, to predict longitudinal asthma control among children with asthma, and to identify features associated with asthma control within each discovered pediatric phenotype.
We applied PP to the Childhood Asthma Management Program study data (n = 1,019) to discover phenotypes on the basis of asthma control between assigned controller therapy groups (budesonide vs. nedocromil). We confirmed PP's ability to discover phenotypes using the Asthma Clinical Research Network/Childhood Asthma Research and Education network data. We next predicted children's asthma control over time and compared PP's performance with that of traditional prediction methods. Last, we identified clinical features most correlated with asthma control in the discovered phenotypes.
Four phenotypes were discovered in both datasets: allergic not obese (A/O), obese not allergic (A/O), allergic and obese (A/O), and not allergic not obese (A/O). Of the children with well-controlled asthma in the Childhood Asthma Management Program dataset, we found more nonobese children treated with budesonide than with nedocromil (P = 0.015) and more obese children treated with nedocromil than with budesonide (P = 0.008). Within the obese group, more A/O children's asthma was well controlled with nedocromil than with budesonide (P = 0.022) or with placebo (P = 0.011). The PP algorithm performed significantly better (P < 0.001) than traditional machine learning algorithms for both short- and long-term asthma control prediction. Asthma control and bronchodilator response were the features most predictive of short-term asthma control, regardless of type of controller medication or phenotype. Bronchodilator response and serum eosinophils were the most predictive features of asthma control, regardless of type of controller medication or phenotype.
Advanced statistical machine learning approaches can be powerful tools for discovery of phenotypes based on treatment response and can aid in asthma control prediction in complex medical conditions such as asthma.
儿科哮喘的潜在炎症和症状控制存在差异。已经研究了多种方法来解决这种异质性,例如聚类方法来寻找表型和预测结果。然而,尚未基于治疗与临床结果之间的关系进行聚类,也未深入研究机器学习方法来预测儿科哮喘的长期结局。
我们使用新颖的机器学习算法预测追求(predictor pursuit,PP),根据控制药物治疗后哮喘控制情况发现儿科哮喘表型,预测哮喘患儿的纵向哮喘控制情况,并确定每个发现的儿科表型中与哮喘控制相关的特征。
我们将 PP 应用于儿童哮喘管理计划研究数据(n=1019),根据指定的控制器治疗组(布地奈德与奈多罗米)之间的哮喘控制情况发现表型。我们使用哮喘临床研究网络/儿童哮喘研究和教育网络数据证实了 PP 发现表型的能力。接下来,我们预测了儿童随时间的哮喘控制情况,并比较了 PP 与传统预测方法的性能。最后,我们确定了在发现的表型中与哮喘控制最相关的临床特征。
在两个数据集均发现了 4 种表型:非肥胖过敏(A/O)、非过敏肥胖(A/O)、过敏肥胖(A/O)和非过敏非肥胖(A/O)。在儿童哮喘管理计划数据集中,控制良好的哮喘患儿中,我们发现接受布地奈德治疗的非肥胖儿童多于接受奈多罗米治疗的儿童(P=0.015),接受奈多罗米治疗的肥胖儿童多于接受布地奈德治疗的儿童(P=0.008)。在肥胖组中,与布地奈德或安慰剂相比,更多的 A/O 儿童的哮喘用奈多罗米控制良好(P=0.022 和 P=0.011)。PP 算法在短期和长期哮喘控制预测方面的表现均显著优于传统机器学习算法(P<0.001)。无论使用何种控制器药物或表型,哮喘控制和支气管扩张剂反应均为短期哮喘控制的最具预测性特征。无论使用何种控制器药物或表型,支气管扩张剂反应和血清嗜酸性粒细胞计数均为哮喘控制的最具预测性特征。
高级统计机器学习方法可作为基于治疗反应发现表型的强大工具,并有助于预测复杂医疗条件(如哮喘)中的哮喘控制。